Umbilical cord blood transplantation (UCBT) has been shown to be curative in a variety of malignant and nonmalignant haematopoietic disorders in children. UCBT has also been offered to adult patients lacking a family or unrelated donor, but with higher rate of transplant-related mortality and infections. 1 Human herpesvirus 6 (HHV-6) is a b-herpes virus, which causes exanthema subitum in children. HHV-6 reactivation has been increasingly recognized in allogeneic haematopoietic stem cell transplant recipients, particularly in UCBT where it has been estimated to occur in 87-100% of the cases. [2] [3] [4] HHV-6 active infection may cause neurological disorders, which, in UCBT recipients, generally manifest with diffuse brain pathology, mainly involving white matter. 5 In allogeneic haematopoietic stem cell transplant adult recipients, HHV-6 has been associated with limbic encephalitis (LE), a CNS disorder confined to the hippocampal regions, which causes anterograde amnesia and epilepsy. 6, 7 However, few data are available about this complication among adult UCBT recipients. We retrospectively analysed all consecutive episodes of HHV-6-related CNS involvement in adult (418 years old) patients receiving UCBT between January 1999 and May 2007 at the Bone Marrow Transplant Unit of Florence. The diagnosis was based on the presence of HHV-6 DNA in cerebrospinal fluid (CSF) once other causes (toxic or infective, including HV1 and HV2, EBV, CMV, BK, JC) of encephalopathy were excluded. PCR was performed according to the protocol of the commercial Herpes Consensus Generic Test (Argene Biosoft, Varilhes, France). Among 15 adult patients receiving UCBT, 2 developed acute neurological symptoms after transplantation; in both the cases, brain magnetic resonance imaging (MRI) and CSF PCR examination were suggestive of a HHV-6-related LE. Conditioning regimen consisted of hyperfractionated total body irradiation (1320 cGy), thiotepa and CY. For GvHD prevention, CYA and methylprednisolone were administered. The patient received both antimicrobial and antiviral (ganciclovir followed by foscarnet and acyclovir) prophylaxis. The early period after transplantation was complicated by mucositis, sepsis (blood culture positive for Staphylococcus epidermidis 3/3), treated with broad-spectrum antibiotics, and haemorrhagic cystitis. PMN and platelet engraftment was achieved on days þ 24 and þ 57, respectively. On day þ 28 the patient developed grade II acute GvHD of the skin, treated with methylprednisolone. On day þ 35, he presented with acute onset of anterograde amnesia, personality changes and confusion; brain MRI showed bilateral hyperintensity of hippocampal regions on T2-weighted images (Figure 1 ). Blood levels of CsA were within therapeutic range. CSF examination revealed mild increase of protein content (56 mg/100 ml), with normal glucose level (66 mg/100 ml) and cell count (2 cells/ml). CSF PCR examination was positive for HHV-6 DNA, then foscarnet 180 mg/kg/day was promptly administered, with rapid resolution of the neurological symptoms and attenuation of MRI changes. However, after 5 days, CMV reactivation and relapse of GvHD (skin and liver, grade IV) occurred, leading to patient death due to multiorgan failure on day þ 58. The retrospective analysis of stored DNA sample of UBC unit by TaqMan chemistry and Abi Prism 7000 Applied Biosystem (Q-HHV6 RealTime Complet Kit Nanogen srl) to exclude HHV-6 transmission through chromosomal integration gave negative result. Conditioning regimen consisted of hyperfractionated total body irradiation (1320 cGy), CY and fludarabine. For GvHD prevention, CsA and mycophenolate mofetil were administered. Antimicrobial and CMV prophylaxis (ganciclovir followed by foscarnet and acyclovir) were administered. PMN and platelet engraftment was achieved on days þ 19 and þ 45, respectively. Acute skin GvHD grade II was demonstrated by biopsy on day þ 18, and treated with high-dose prednisone. On day þ 32, the patient presented with confusion, blurred vision and generalized tonic-clonic seizures, associated with marked hyponatremia suggestive of a syndrome of inappropriate antidiuretic hormone (SIDAH). Plasma levels of CsA were within the therapeutic range. EEG showed bitemporal rhythmic slow waves; brain MRI disclosed hyperintensity areas over both hippocampal regions (Figure 1 ). The CSF examination revealed slight lymphocyte-predominant pleocytosis of 8 cells/ml, with normal protein (34 mg/100 ml) and glucose (87 mg/100 ml) content. CSF and plasma PCR tested positive for HHV-6 DNA. Chromosomally integrated HHV-6 into DNA from both UBC units was excluded by real-time PCR analysis. Foscarnet (180 mg/kg/day) treatment resulted in a rapid improvement of the neurological symptoms, and the brain MRI images showed an attenuation of hippocampal hyperintensity. A second CSF PCR was negative for viral DNA. The patient died 6 months later for leukaemia relapse.
Reactivation of HHV-6 has been widely documented in transplanted patients. UCBT recipients have the highest risk of herpesvirus reactivation, probably due to late immune reconstitution. 8 The diagnosis of HHV-6-related CNS disorder is based on the detection of viral genome in CSF samples, once any other causes of brain damage, such as toxicity from CsA or tacrolimus, have been excluded. Although two variants of HHV-6 (A and B) exist, the most frequently reported in association with clinical syndromes is HHV-6B. 9 One of the best characterized brain disorders associated with HHV-6 after transplantation is LE, in which the neurological impairment, and MRI changes, are confined to the limbic system, causing confusion, memory problems and seizures. 6, 7 The relative restriction of HHV-6 active infection to the medial temporal lobe structures is not completely understood, but probably reflects the high HHV-6-specific tropism for hippocampal astrocytes demonstrated by autopsy studies in haematopoietic stem cell transplant recipients. 10 In a previous retrospective study, a high (3/14) incidence of HHV-6 encephalitis has been reported following UCBT; two of the three patients had signs and symptoms of temporal lobe involvement, and all were adolescents (that is, aged 12, 16 and 18). 8 We first documented a high incidence of HHV-6-related LE in adult (more than 18 years old) UCBT individuals. This incidence (13%) is much higher compared with that reported in patients receiving haematopoietic stem cell transplant from other sources, in whom this complication is considered relatively rare. A possible explanation of this difference is the absence of HHV-6-specific T memory cells in umbilical cord blood. 11 However, the higher degree of immunosuppression obtained in UCBT recipients to avoid transplant rejection could contribute to the viral escape from immune surveillance, and to its higher pathogenicity. Another harmful factor for HHV-6 reactivation is an HLAmismatched or unrelated graft, which is more frequent in patients who have undergone UCBT. 2 Moreover, a higher viral reactivation and frequency of HHV-6-related complications in patients with GvHD has been reported; 7 in both our cases, the onset of acute GvHD had preceded the development of LE by a few days. The association between GvHD and HHV-6 complications is, however, still unclear. Another explanation for high viral DNA load in transplanted individuals is the transmission through UBCT due Letter to the Editor
